TrialThe Prostate2019

Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.

Oliver Sartor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.